ChromoCure and Genome Research Group Expand Collaborative Reach With Euro Zone Launch of Pathologist Research Program
2010年4月28日 - 11:15PM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) and Genome Research Group (GRG)
announced today the Euro Zone launch of its Pathologist
Collaborative Research (PCR) Program in support of the
groundbreaking Project Boveri: Find the Cure Initiative; as the
companies leverage their combined technologies, research knowledge
and industry relationships.
The Company will announce programs and specifics for each
Euro-Zone country as its lead partner in the area is selected. The
Company's goal is to establish a worldwide network of diagnostic
and research collaborations with continuous collection of cancer
specimen and test result data.
The Company's recently announced merger with GRG prepares the
group for a leading role in the new era of cancer research,
detection, and therapy.
Earlier this year, the Company launched its groundbreaking PCR
program whereby selected pathologists provide cell samples of
historical or current patients to the Company for analysis with its
chromosomal scanning technology. Full results of the scan and
analysis will be provided to the pathologist. Patient information
or history is neither required nor supplied for the purpose of this
research. The scan results will be compared to the diagnosis of the
pathologist. The Company will continuously build its database of
results as part of its larger clinical pre-trial efforts.
Research has conclusively and irrefutably demonstrated
aneuploidy a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's proprietary technology and understanding of cancer
compliment GRG's non-toxic and non-invasive approaches to cancer
therapy and cure research.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research.
As a direct result of the Company's recently announced agreement
with GRG, ChromoCure recently released expanded specifications and
significant capability enhancements of its next generation CS300
Chromosomal Scanner technology to accommodate anticipated increased
research demand.
ChromoCure's proprietary Chromosomal Scanning technology has
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. With a 100% effective accuracy and specificity, the company
believes its technology superior to other detection approaches
presently relied upon by pathologists, including genetic or protein
biomarker detection. The Company's technology scans and detects the
ultimate 'marker' for cancer guaranteeing 100% accuracy and
specificity.
GRG's advanced Therapeutic Modeling Protocols, together with
ChromoCure's landmark Chromosomal Scanning Technology, further
strengthens the Company's leadership in Cancer Detection, Therapy
and Cure by providing on-demand, real-time cancer progression
analysis to monitor and determine treatment efficacy.
The Company's recently announced merger with GRG will be of
mutual benefit in advancement of their shared objective; as a
focused Cancer Therapy and Cure Research & Development
organization. The announced merger and acquisition of GRG prepares
the group for a leading role in this new era of cancer research,
detection and therapy.
The combined entity will possess complementary detection and
therapeutic technology and protocols. Management believes the
transaction to be of significant long-term shareholder value and
furthers the Company's transition to research, technology
development, and licensing as a source of significant long-term and
recurring revenues and equity appreciation.
The Company believes its technologies provide the foundation for
significant advances in diagnosis, therapy and cure. The Company
recently announced its Therapy and Cure initiatives with Project
Boveri: Find the Cure. Shareholders can expect further updates on
research collaborations, laboratory partnerships, and research
initiatives.
About ChromoCure ChromoCure develops and
provides proprietary cancer detection systems and related
therapeutic technologies. The Company's proprietary CS200
Chromosomal Scanner has been proven accurate and efficient in the
measurement of the unique genomic characteristic found in 100% of
all cancers and never found in normal cells. The Company's
detection technology has an effective accuracy of 100% for all
cancers at all stages. The Company believes its technology will
become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
About Genome Research Group The Genome
Research Group develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary cancer detection system locates and measures unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has a proven
and effective accuracy of 100% for all cancers at all stages. The
Company's proprietary Therapeutic Modeling Protocols provide
statistical modeling and prediction tools for the measurement and
monitoring of cancer progression and remission. The Company also
applies its technology and knowledge to cancer cure and
therapeutics research. GRG owns proprietary techniques for
non-toxic and non-invasive cancer therapy utilizing hypothermic
modulation and resonance. GRG's advanced Therapeutic Modeling and
Treatment Protocols combined with its industry and medical research
collaborations validate its leadership role in Cancer Detection,
Therapy and Cure.
Safe-Harbor Statement This release
contains statements or projections regarding future performance
that is forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those projected as a result of certain risks and
uncertainties. The company's filings contain various RISK FACTORS
(and are incorporated herein by reference) and should be read
before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com
Tel: 1.775.636.6548 Genome Research Group, Inc.
www.genomeresearchgroup.com info@genomeresearchgroup.com Tel: +011
(44) 20 7101 9475
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024